Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8056 to 8070 of 9008 results

  1. Magrolimab with azacitidine for untreated myelodysplastic syndromes [ID3978]

    Discontinued Reference number: GID-TA10861

    Technology appraisal guidance
    Discontinued

  2. Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]

    In development Reference number: GID-TA10998 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]

    In development Reference number: GID-TA10684 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Preterm labour and birth - predicting preterm birth

    Discontinued Reference number: GID-NG10384

    NICE guideline
    Discontinued

  5. Workplace health - older employees

    Discontinued Reference number: GID-PHG59

    NICE guideline
    Discontinued

  6. Intrapartum care for healthy women and babies - angle of episiotomy

    Discontinued Reference number: GID-NG10394

    NICE guideline
    Discontinued

  7. Preterm labour and birth - timing of cord clamping

    Discontinued Reference number: GID-NG10396

    NICE guideline
    Discontinued

  8. Atopic Dermatitis (Eczema)

    Discontinued Reference number: GID-NG10289

    NICE guideline
    Discontinued

  9. Non-invasive skin closure devices for surgical incisions (MT775)

    In development Reference number: GID-MT593 Expected publication date: TBC

    Medical technologies guidance
    In development

  10. Elivaldogene autotemcel for treating cerebral adrenoleukodystrophy [ID1284]

    Discontinued Reference number: GID-HST10038

    Highly specialised technologies guidance
    Discontinued

  11. Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]

    Discontinued Reference number: GID-TAG423

    Technology appraisal guidance
    Discontinued

  12. Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]

    Discontinued Reference number: GID-TA10018

    Technology appraisal guidance
    Discontinued

  13. Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897]

    Discontinued Reference number: GID-TAG526

    Technology appraisal guidance
    Discontinued

  14. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued Reference number: GID-TAG415

    Technology appraisal guidance
    Discontinued

  15. Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]

    Discontinued Reference number: GID-TAG440

    Technology appraisal guidance
    Discontinued